Clinical Trials Logo

Benzodiazepine Dependence clinical trials

View clinical trials related to Benzodiazepine Dependence.

Filter by:

NCT ID: NCT06359314 Not yet recruiting - Anxiety Disorders Clinical Trials

Anxiety Lowering and Deprescribing Through Emotion Regulation

ALDER
Start date: April 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to test ALDER (Anxiety Lowering and Deprescribing through Emotion Regulation), an online self-guided positive emotion intervention, in patients over the age of 65 who are candidates for benzodiazepine receptor agonist (BZRA, commonly called benzos, or z-drugs) deprescribing. The main questions it aims to answer are: - Is ALDER relevant to and satisfactory for older adult BZRA users? - Does ALDER help to increase positive emotions and decrease anxiety, trouble sleeping, and use of BZRA medications? Participants will complete the 5-week online self-guided ALDER intervention as well as two survey assessments, one before the intervention and one after.

NCT ID: NCT06250842 Recruiting - Depression, Anxiety Clinical Trials

Benzodiazepine Impact on Cognitive Function: fNIRs and PET/MRI Study

Start date: February 11, 2024
Phase:
Study type: Observational

This study explores the impact of long-term benzodiazepine (BZDs) use on cognitive function and associated neuroimaging markers. While BZDs are established treatments for conditions like anxiety and insomnia, recent warnings highlight risks, including neurocognitive effects. Neuroimaging studies indicate potential neuroprotective effects of BZDs. Functional near-infrared spectroscopy (fNIRS) measures cerebral cortex function during cognitive tasks. Combining fNIRS with mood and cognitive scales, this study assesses cortical activation. 2-deoxy-2-fluoro-D-glucose-positron emission tomography (FDG-PET) evaluates brain metabolism. DPA-714 PET assesses neuroinflammation. The primary objective is to compare brain functional activation, metabolism, and neuroinflammatory levels between long-term BZD users and non-users. This comprehensive approach aims to provide insights into BZD effects on cognition and associated brain markers.

NCT ID: NCT05935553 Not yet recruiting - Clinical trials for Benzodiazepine Dependence

Baclofen for Improving Benzodiazepine Titration in Benzodiazepine Dependence

BABET
Start date: March 1, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

Benzodiazepines and related molecules are among the most prescribed psychotropic treatments in France and Europe. 13.4% of the French population had at least one reimbursement of benzodiazepines in 2015, which places France second in Europe. However, the chronic use of benzodiazepines is a source of numerous complications, particularly addictive. To date, there is no authorized pharmacological treatment for benzodiazepine withdrawal. Baclofen is a gamma-aminobutyric acid (GABA)-B agonist, a pharmacological receptor that regulates GABA-A, the target of benzodiazepines. The pharmacological mechanisms of baclofen are therefore related to those of benzodiazepines. Empirical use outside of the MA has shown that baclofen can facilitate the reduction of benzodiazepines in cases of severe addiction, but this pharmaceutical interest remains to be demonstrated in a comparative study. The main objective of the project is to evaluate the efficacy of baclofen, compared to placebo, in reducing benzodiazepine doses in patients with benzodiazepine use disorder (BUD).

NCT ID: NCT05765656 Not yet recruiting - Anxiety Clinical Trials

Effectiveness of a Joint General Practitioner-Pharmacist Intervention on Benzodiazepine Deprescribing in the Elderly

BESTOPH-MG
Start date: March 15, 2023
Phase: N/A
Study type: Interventional

Benzodiazepines or related drug (BZDR) are consumed for hypnotic or anxiolytic purposes in most cases. The consequences of BZDR are multiple with an increased risk of daytime sedation, balance disorders leading to falls and fractures, cognitive disorders, road accidents and dementia. Given their comorbidities, physiological changes, and multiple medications, the elderly are more at risk of suffering from BZDR adverse events. Interprofessional collaboration has shown efficacy in improving prescribing appropriateness and may affect patients outcomes positively. Morever, motivational interviews (MI) may reduce the extent of substance abuse compared to no intervention.

NCT ID: NCT04572750 Active, not recruiting - Clinical trials for Benzodiazepine Dependence

Promoting Benzodiazepine Cessation Through an Electronically-delivered Patient Self-management Intervention

EMPOWER-ED
Start date: June 1, 2022
Phase: N/A
Study type: Interventional

Benzodiazepines (e.g., Ativan, Xanax) are widely prescribed medications that are used mainly to treat anxiety and sleeping difficulties. Long-term use of benzodiazepine carries risks of physical dependence, addiction, falls and other accidents, and problems in thinking/concentrating. Researchers in Canada developed a printed self-help packet that enabled many individuals to reduce or cease taking benzodiazepines on their own. This study is designed to tailor that packet to the Veteran population, convert it to an app that people can use on their laptop or smart phone, and test whether the app helps promote benzodiazepine prescribing.

NCT ID: NCT04533230 Withdrawn - Clinical trials for Substance Use Disorders

Prevention of Benzodiazepine Misuse in Primary Care

Start date: September 1, 2020
Phase: N/A
Study type: Interventional

Benzodiazepines and benzodiazepine-like hypnotics (z-drugs) are prevalent and addictive narcotics. Guidelines recommend restricted prescription of these drugs for anxiety and insomnia. The majority of benzodiazepine prescriptions are written for these disorders by physicians (GPs) in primary health care. Primary health care is thus an important arena for efforts to reduce access to benzodiazepines in order to lower the number of new users and users at risk of dependency. This trial evaluates whether a brief educational intervention in primary health care followed by 12 months of feedback on prescription data changes the prescription of benzodiazepines and benzodiazepine-like hypnotics.

NCT ID: NCT03971097 Completed - Clinical trials for Alcohol Use Disorder

The Effect of Self-Forgiveness on Self-Stigma in Addiction.

Start date: August 1, 2019
Phase: N/A
Study type: Interventional

This study has an experimental design and will examine the difference in pre-test and post-test data on the Self-Forgiveness Dual Process Scale (SFDPS) (Griffin, Worthington, Davis, Hook, & Maguen, 2018) and the Substance Abuse Self-Stigma Scale (SASSS) (Luoma et al., 2013). Data will be collected from two groups of participants receiving counseling at the short-term rehabilitation facility located at University of Pittsburgh Medical Center's (UPMC). Individuals who agree to participate in the study will be randomly assigned to either the experimental group (EG) or the control group (CG). Data collected will include pre-test SFDPS and SASSS scores for the EG and the CG (collected within 24-hours of admission), and post-test SFDPS and SASSS scores for the EG and CG (collected after 14 days). ANCOVA will be used to analyze the pre-test and post-test data recorded from participants' scores.

NCT ID: NCT03937180 Completed - Clinical trials for Benzodiazepine Dependence

Blended Care for the Discontinuation of Benzodiazepine Use

Big Bird
Start date: June 24, 2019
Phase: N/A
Study type: Interventional

This study aims to compare two strategies performed by GPs to help patients taking benzodiazepines on a daily basis for at least six months to discontinue their use. The first strategy consists of the usual or standard support provided by the GP, which often starts with a discontinuation advice or letter, the second is blended support where face-to-face consultations with the GP are alternated with web-based self-learning by the patient.

NCT ID: NCT03192514 Terminated - Prevention Clinical Trials

Electronic Deprescribing Tool for the Prevention of PIP

Start date: October 2, 2017
Phase: N/A
Study type: Interventional

This study is a cluster randomized control trial aimed to measure the effectiveness of an educational knowledge transfer intervention to prescribers on the discontinuation of two targeted classes: Benzodiazepines andNon-benzodiazepine hypnotics.

NCT ID: NCT02475538 Recruiting - Clinical trials for Benzodiazepine Dependence

Electroacupuncture for Tapering Off Long-term Benzodiazepine Use

Start date: July 2015
Phase: N/A
Study type: Interventional

This study aims to examine the efficacy of electroacupuncture for tapering benzodiazepines in long-term users. All eligible subjects will be randomized in a ratio of 1:1 to (1) Electroacupuncture combined with gradual tapering; and (2) Placebo acupuncture combined with gradual tapering.